GlassScriptPhysician profile
Atul Vachhani
NPI 1609890748
$2,731.89
in general payments reported to CMS, 2019-2025
16 companies · $679 in 2025
The $679 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $304 · 2020: $85.00 · 2021: $151 · 2022: $636 · 2023: $337 · 2024: $541 · 2025: $679.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,557.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,556.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,596.88 | 2019-2025 | Rinvoq, Skyrizi, Viberzi |
| Janssen Biotech, INC. | $260.97 | 2020-2023 | Stelara |
| Boston Scientific Corporation | $234.08 | 2022-2025 | Resolution 360 Clip, Apollo Esg Nxt System, General - Gi Dilatation |
| Gilead Sciences, INC. | $204.47 | 2019-2025 | |
| Aimmune Therapeutics, INC. | $98.85 | 2025 | Zenpep |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $72.18 | 2019-2021 | |
| Shionogi INC | $63.13 | 2019 | |
| Pfizer INC. | $52.65 | 2019-2022 | |
| Madrigal Pharmaceuticals | $44.16 | 2024-2025 | Resmetirom, Rezdiffra |
| Medtronic, INC. | $17.83 | 2022 | |
| Allergan, INC. | $16.71 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $15.19 | 2025 | Iqirvo |
| Novo Nordisk INC | $14.53 | 2025 | Wegovy |
| Intercept Pharmaceuticals, INC. | $13.65 | 2022 | |
| Celgene Corporation | $13.34 | 2022 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Braintree Laboratories, INC. | $13.27 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Atul Vachhani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.